up-to-date with a click!
Update June, 2018
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications June 2018

Add on treatments

  1. Blanka SS, Gabor O, Hajnal K. Pharaceutical chemical characterization of ezetimibe. Acta pharmaceutica Hungarica 2016; 86:133-139. http://www.ncbi.nlm.nih.gov/pubmed/?term=29870599
  2. Hadzi-Petrushev N, Dimovska K, Jankulovski N et al. Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease's Statin Therapy in Men. Advances in pharmacological sciences 2018; 2018:4673061. http://www.ncbi.nlm.nih.gov/pubmed/?term=29887885
  3. Ballantyne CM, Banach M, Mancini GBJ et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29910030
  4. Mason RP, Dawoud H, Jacob RF et al. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 103:1231-1237. http://www.ncbi.nlm.nih.gov/pubmed/?term=29864903
  5. Bohula EA, Wiviott SD, Giugliano RP et al. Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 137:2662-2663. http://www.ncbi.nlm.nih.gov/pubmed/?term=29891625
  6. Cordero A, Bertomeu-Gonzalez V, Rodriguez-Manero M. Letter by Cordero et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 137:2658-2659. http://www.ncbi.nlm.nih.gov/pubmed/?term=29891623
  7. Del Pinto R, Ferri C, Borghi C. Letter by Del Pinto et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 137:2654-2655. http://www.ncbi.nlm.nih.gov/pubmed/?term=29891621
  8. Koh KK. Letter by Koh Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 137:2660-2661. http://www.ncbi.nlm.nih.gov/pubmed/?term=29891624
  9. Thomopoulos C, Michalopoulou H. Letter by Thomopoulos and Michalopoulou Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 137:2656-2657. http://www.ncbi.nlm.nih.gov/pubmed/?term=29891622
  10. Vilahur G, Ben-Aicha S, Diaz E et al. Phytosterols and inflammation. Curr Med Chem 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29932029
  11. Selak V, Webster R, Stepien S et al. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Heart 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29954855
  12. Turk Veselic M, Zorz N, Erzen B et al. Improvement of arterial wall phenotype in subjects at moderate cardiovascular risk induced by very low-dose fluvastatin/valsartan combination: a pilot study. International angiology : a journal of the International Union of Angiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29952159
  13. Fujisue K, Nagamatsu S, Shimomura H et al. Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29925472
  14. Simon TG, Corey KE, Cannon CP et al. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29903515
  15. Taylor BA, Panza G, Ballard KD et al. Creatine supplementation does not alter the creatine kinase response to eccentric exercise in healthy adults on atorvastatin. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29945780
  16. Deloughery EP, Prasad V. If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis. Journal of general internal medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29869138
  17. Tseng CH. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver international : official journal of the International Association for the Study of the Liver 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29956875
  18. Bird JK, Calder PC, Eggersdorfer M. The Role of n-3 Long Chain Polyunsaturated Fatty Acids in Cardiovascular Disease Prevention, and Interactions with Statins. Nutrients 2018; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29914111
  19. Jurisic A, Jurisic Z, Lefkou E et al. Pravastatin and-L-arginine combination improves umbilical artery blood flow and neonatal outcomes in dichorionic twin pregnancies through an nitric oxide-dependent vasorelaxant effect. Vascul Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29879462

Adherence

  1. Litke J, Spoutz L, Ahlstrom D et al. Impact of the clinical pharmacy specialist in telehealth primary care. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2018; 75:982-986. http://www.ncbi.nlm.nih.gov/pubmed/?term=29941537
  2. Nanna MG, Navar AM, Zakroysky P et al. Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry. JAMA cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898219
  3. Tomilova DI, Karpov YA, Lopukhova VV. [Long-Term Statin Adherence in Patients with Stable Angina after Coronary Stenting]. Kardiologiia 2018:65-71. http://www.ncbi.nlm.nih.gov/pubmed/?term=29870326
  4. Rasmussen L, Pratt N, Hansen MR et al. Using the "proportion of patients covered" and the Kaplan-Meier survival analysis to describe treatment persistence. Pharmacoepidemiol Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29952045
  5. Lansberg P, Lee A, Lee ZV et al. Nonadherence to statins: individualized intervention strategies outside the pill box. Vasc Health Risk Manag 2018; 14:91-102. http://www.ncbi.nlm.nih.gov/pubmed/?term=29872306

Atherosclerosis & Imaging

  1. Ida J, Kotani K, Miyoshi T et al. High Baseline Lipoprotein(a) Level as a Risk Factor for Coronary Artery Calcification Progression: Sub-analysis of a Prospective Multicenter Trial. Acta medica Okayama 2018; 72:223-230. http://www.ncbi.nlm.nih.gov/pubmed/?term=29925999
  2. Kozlov SG, Khamchieva LS, Pogorelova OA et al. [Dynamics of asymptomatic atherosclerosis of carotid arteries depending on the achieved level of cholesterol in moderate-risk patients]. Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery 2018; 24:11-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=29924771
  3. Epure AM, Leyvraz M, Mivelaz Y et al. Risk factors and determinants of carotid intima-media thickness in children: protocol for a systematic review and meta-analysis. BMJ Open 2018; 8:e019644. http://www.ncbi.nlm.nih.gov/pubmed/?term=29866720
  4. Shekar C, Budoff M. Calcification of the heart: mechanisms and therapeutic avenues. Expert Rev Cardiovasc Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29860888
  5. May AN, Lin LIP, Feneley M. Coronary Plaque Regression After Statin Therapy. Heart, lung & circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29895485
  6. Turk Veselic M, Zorz N, Erzen B et al. Improvement of arterial wall phenotype in subjects at moderate cardiovascular risk induced by very low-dose fluvastatin/valsartan combination: a pilot study. International angiology : a journal of the International Union of Angiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29952159
  7. Fujisue K, Nagamatsu S, Shimomura H et al. Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29925472
  8. Miedema MD, Dardari ZA, Kianoush S et al. Statin Eligibility, Coronary Artery Calcium, and Subsequent Cardiovascular Events According to the 2016 United States Preventive Services Task Force (USPSTF) Statin Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29899017
  9. Zhao Y, Gao H, He J et al. Co-delivery of LOX-1 siRNA and statin to endothelial cells and macrophages in the atherosclerotic lesions by a dual-targeting core-shell nanoplatform: A dual cell therapy to regress plaques. J Control Release 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29885417
  10. Rizwan M, Faateh M, Aridi HD et al. Statins reduce mortality and failure to rescue after carotid artery stenting. Journal of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29914834
  11. Lee SE, Chang HJ, Sung JM et al. Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM (Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging) Study. JACC. Cardiovascular imaging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29909109
  12. Ikegami Y, Inoue I, Inoue K et al. The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. NPJ aging and mechanisms of disease 2018; 4:7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29951223
  13. Sequeira Gross T, Naito S, Neumann N et al. Does statin therapy impact the proximal aortopathy in aortic valve disease? QJM : monthly journal of the Association of Physicians 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29917097

Atorvastatin/Rosuvastatin

  1. Bai X, Zhang B, Wang P et al. Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. Acta pharmacologica Sinica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29950617
  2. Akouchekian S, Omranifard V, Moshfegh P et al. The Effect of Atorvastatin on Obsessive-compulsive Symptoms of Refractory Obsessive-compulsive Disorder (Add-on Therapy). Advanced biomedical research 2018; 7:90. http://www.ncbi.nlm.nih.gov/pubmed/?term=29930930
  3. Jones HM, Fang Z, Sun W et al. Erratum: Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro. American journal of cancer research 2018; 8:915. http://www.ncbi.nlm.nih.gov/pubmed/?term=29888764
  4. Lemaster KA, Frisbee SJ, DuBois L et al. CHRONIC ATORVASTATIN AND EXERCISE CAN PARTIALLY REVERSE ESTABLISHED SKELETAL MUSCLE MICROVASCULOPATHY IN METABOLIC SYNDROME. American journal of physiology. Heart and circulatory physiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29932769
  5. Ayad MT, Taylor BD, Menon R. Regulation of p38 mitogen-activated kinase-mediated fetal membrane senescence by statins. American journal of reproductive immunology (New York, N.Y. : 1989) 2018:e12999. http://www.ncbi.nlm.nih.gov/pubmed/?term=29911323
  6. Fuentes-Orozco C, Garcia-Salazar SJ, Gomez-Navarro B et al. Anti-Inflammatory Effect of Atorvastatin on the Kidney Graft of Living Donor Transplants. Annals of transplantation 2018; 23:442-449. http://www.ncbi.nlm.nih.gov/pubmed/?term=29955032
  7. Usategui-Martin R, Vega G, Abad-Manteca L et al. Role of Bone Morphogenetic Protein 2 (BMP-2) Polymorphisms in Bone Mineral Density after the Start of Treatment with Atorvastatin. Basic & clinical pharmacology & toxicology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29956474
  8. Soko ND, Masimirembwa C, Dandara C. A cost effective RFLP method to genotype Solute carrier organic anion 1B1 (SLCO1B1) c.1929A>C (p.Leu643Phe, rs34671512); a variant with potential effect on rosuvastatin pharmacokinetics. BMC research notes 2018; 11:384. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898760
  9. Santos C, Dourado DM, Silva B et al. Effect of Ischemic Postconditioning and Atorvastatin in the Prevention of Remote Lung Reperfusion Injury. Brazilian journal of cardiovascular surgery 2018; 33:115-121. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898139
  10. Gambhire VM, Salunkhe SM, Gambhire MS. Atorvastatin loaded lipid nanoparticles: Antitumor activity studies on MCF-7 breast cancer cells. Drug development and industrial pharmacy 2018:1-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=29936872
  11. Verbree-Willemsen L, Zhang YN, Gijsberts CM et al. LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trial. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898827
  12. Taylor BA, Panza G, Ballard KD et al. Creatine supplementation does not alter the creatine kinase response to eccentric exercise in healthy adults on atorvastatin. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29945780
  13. Vershinina EO, Repin AN, Timofeev MS, Udut VV. [Prevention of periprocedural kidney ingury by loading doses of statins in elective percutaneous small es, Cyrillicoronary interventions]. Kardiologiia 2018:20-29. http://www.ncbi.nlm.nih.gov/pubmed/?term=29894673
  14. Toure PS, Leye YM, Diop MM et al. [Thrombocytopenia purpura, myositis and cytolitic hepatitis: a rare association linked with atorvastatin]. Le Mali medical 2013; 28:49-51. http://www.ncbi.nlm.nih.gov/pubmed/?term=29925222
  15. Peng Y, Ou BQ, Li HH et al. Synergistic Effect of Atorvastatin and Folic Acid on Cardiac Function and Ventricular Remodeling in Chronic Heart Failure Patients with Hyperhomocysteinemia. Medical science monitor : international medical journal of experimental and clinical research 2018; 24:3744-3751. http://www.ncbi.nlm.nih.gov/pubmed/?term=29863106
  16. Nakashima Y, Miyagi-Shiohira C, Noguchi H, Omasa T. Atorvastatin Inhibits the HIF1alpha-PPAR Axis, Which Is Essential for Maintaining the Function of Human Induced Pluripotent Stem Cells. Molecular therapy : the journal of the American Society of Gene Therapy 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29929789
  17. Antonopoulos N, Machairas G, Migias G et al. Hydrophilic Interaction Liquid Chromatography-Electrospray Ionization Mass Spectrometry for Therapeutic Drug Monitoring of Metformin and Rosuvastatin in Human Plasma. Molecules (Basel, Switzerland) 2018; 23. http://www.ncbi.nlm.nih.gov/pubmed/?term=29954074
  18. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. N Engl J Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898369
  19. Rezazadeh M, Parandeh M, Akbari V et al. Incorporation of rosuvastatin-loaded chitosan/chondroitin sulfate nanoparticles into a thermosensitive hydrogel for bone tissue engineering: preparation, characterization, and cellular behavior. Pharmaceutical development and technology 2018:1-23. http://www.ncbi.nlm.nih.gov/pubmed/?term=29863957
  20. Huo Z, Kong Y, Meng M et al. Atorvastatin enhances endothelial adherens junctions through promoting VE-PTP gene transcription and reducing VE-cadherin-Y731 phosphorylation. Vascul Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29894844
  21. Tang R, Shi J, Li X et al. Effects of Atorvastatin on Surgical Treatments of Chronic Subdural Hematoma. World neurosurgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29920396
  22. Du RX, Ye P, Yan GT et al. [The effect of rosuvastatin therapy on CCR2 expression in mononuclear cells and its upstream pathway]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 2016; 32:202-206. http://www.ncbi.nlm.nih.gov/pubmed/?term=29931877
  23. Zhou CZ, Pan SL, Lin H et al. [Effects of rosuvastatin in homocysteine induced mouse vascular smooth muscle cell dedifferentiation and endoplasmic reticulum stress and its mechanisms]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 2018; 34:43-48. http://www.ncbi.nlm.nih.gov/pubmed/?term=29926658
  24. Ren H, Ding M, Ma H et al. [Protective effects of combined use of atorvastatin and low molecular weight heparin on the inflammatory reaction and pulmonary functions in rats with sepsis]. Zhonghua wei zhong bing ji jiu yi xue 2016; 28:427-432. http://www.ncbi.nlm.nih.gov/pubmed/?term=29920039

Basic science

  1. Blanka SS, Gabor O, Hajnal K. Pharaceutical chemical characterization of ezetimibe. Acta pharmaceutica Hungarica 2016; 86:133-139. http://www.ncbi.nlm.nih.gov/pubmed/?term=29870599
  2. Feng D, Ge C, Tan ZY et al. Isoflavones enhance pharmacokinetic exposure of active lovastatin acid via the upregulation of carboxylesterase in high-fat diet mice after oral administration of Xuezhikang capsules. Acta pharmacologica Sinica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29921884
  3. Jones HM, Fang Z, Sun W et al. Erratum: Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro. American journal of cancer research 2018; 8:915. http://www.ncbi.nlm.nih.gov/pubmed/?term=29888764
  4. Lemaster KA, Frisbee SJ, DuBois L et al. CHRONIC ATORVASTATIN AND EXERCISE CAN PARTIALLY REVERSE ESTABLISHED SKELETAL MUSCLE MICROVASCULOPATHY IN METABOLIC SYNDROME. American journal of physiology. Heart and circulatory physiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29932769
  5. Ayad MT, Taylor BD, Menon R. Regulation of p38 mitogen-activated kinase-mediated fetal membrane senescence by statins. American journal of reproductive immunology (New York, N.Y. : 1989) 2018:e12999. http://www.ncbi.nlm.nih.gov/pubmed/?term=29911323
  6. Barros S, Montes R, Quintana JB et al. Chronic environmentally relevant levels of simvastatin disrupt embryonic development, biochemical and molecular responses in zebrafish (Danio rerio). Aquatic toxicology (Amsterdam, Netherlands) 2018; 201:47-57. http://www.ncbi.nlm.nih.gov/pubmed/?term=29879595
  7. Usategui-Martin R, Vega G, Abad-Manteca L et al. Role of Bone Morphogenetic Protein 2 (BMP-2) Polymorphisms in Bone Mineral Density after the Start of Treatment with Atorvastatin. Basic & clinical pharmacology & toxicology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29956474
  8. Sarangi B, Jana U, Sahoo J et al. Systematic approach for the formulation and optimization of atorvastatin loaded solid lipid NANOAPARTICLES using response surface methodology. Biomedical microdevices 2018; 20:53. http://www.ncbi.nlm.nih.gov/pubmed/?term=29946758
  9. Chujan S, Suriyo T, Ungtrakul T et al. Potential candidate treatment agents for targeting of cholangiocarcinoma identified by gene expression profile analysis. Biomedical reports 2018; 9:42-52. http://www.ncbi.nlm.nih.gov/pubmed/?term=29930804
  10. Li H, Chen MH, Ibrahim JG et al. Bayesian inference for network meta-regression using multivariate random effects with applications to cholesterol lowering drugs. Biostatistics (Oxford, England) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29912318
  11. Dong R, Ma G, Zhang S et al. Simvastatin reverses multiple myeloma serum-induced prothrombotic phenotype in endothelial cells via ERK 1/2 signalling pathway. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29916838
  12. Santos C, Dourado DM, Silva B et al. Effect of Ischemic Postconditioning and Atorvastatin in the Prevention of Remote Lung Reperfusion Injury. Brazilian journal of cardiovascular surgery 2018; 33:115-121. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898139
  13. Zhao J, Xu C, Yao J et al. Statins and Thyroid Carcinoma: a Meta-Analysis. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018; 47:1422-1431. http://www.ncbi.nlm.nih.gov/pubmed/?term=29929194
  14. Mohammadian M, Sadeghipour HR, Jahromi GP et al. Simvastatin and bone marrow-derived mesenchymal stem cells (BMSCs) affects serum IgE and lung cytokines levels in sensitized mice. Cytokine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29914792
  15. Gambhire VM, Salunkhe SM, Gambhire MS. Atorvastatin loaded lipid nanoparticles: Antitumor activity studies on MCF-7 breast cancer cells. Drug development and industrial pharmacy 2018:1-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=29936872
  16. Villani C, Sacchetti G, Bagnati R et al. Correction: Lovastatin fails to improve motor performance and survival in methyl-CpG-binding protein2-null mice. eLife 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29957179
  17. Tong H, Zhang X, Meng X et al. Simvastatin Inhibits Activation of NADPH Oxidase/p38 MAPK Pathway and Enhances Expression of Antioxidant Protein in Parkinson Disease Models. Frontiers in molecular neuroscience 2018; 11:165. http://www.ncbi.nlm.nih.gov/pubmed/?term=29872377
  18. Chen YA, Shih HW, Lin YC et al. Simvastatin Sensitizes Radioresistant Prostate Cancer Cells by Compromising DNA Double-Strand Break Repair. Frontiers in pharmacology 2018; 9:600. http://www.ncbi.nlm.nih.gov/pubmed/?term=29950990
  19. Zhong WB, Tsai YC, Chin LH et al. A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model. Int J Mol Sci 2018; 19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29932104
  20. Gao WY, Chen PY, Chen SF et al. Pinostrobin inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression through the modulation of FoxO3a protein in HepG2 cells. Journal of agricultural and food chemistry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29862818
  21. Mizrahi M, Adar T, Lalazar G et al. Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for "Safer Drug" Formulation that Prevents Drug-induced Liver Injury. Journal of clinical and translational hepatology 2018; 6:127-134. http://www.ncbi.nlm.nih.gov/pubmed/?term=29951356
  22. Zhao Y, Gao H, He J et al. Co-delivery of LOX-1 siRNA and statin to endothelial cells and macrophages in the atherosclerotic lesions by a dual-targeting core-shell nanoplatform: A dual cell therapy to regress plaques. J Control Release 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29885417
  23. Wegner A, Pavlovic D, Haussmann-Vopel S, Lehmann C. Impact of lipid modulation on the intestinal microcirculation in experimental sepsis. Microvascular research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29859746
  24. Cai WY, Zhuang Y, Yan F et al. Effect of survivin downregulation by simvastatin on the growth and invasion of salivary adenoid cystic carcinoma. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29956779
  25. Nakashima Y, Miyagi-Shiohira C, Noguchi H, Omasa T. Atorvastatin Inhibits the HIF1alpha-PPAR Axis, Which Is Essential for Maintaining the Function of Human Induced Pluripotent Stem Cells. Molecular therapy : the journal of the American Society of Gene Therapy 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29929789
  26. Antonopoulos N, Machairas G, Migias G et al. Hydrophilic Interaction Liquid Chromatography-Electrospray Ionization Mass Spectrometry for Therapeutic Drug Monitoring of Metformin and Rosuvastatin in Human Plasma. Molecules (Basel, Switzerland) 2018; 23. http://www.ncbi.nlm.nih.gov/pubmed/?term=29954074
  27. Jaskiewicz A, Pajak B, Litwiniuk A et al. Geranylgeraniol Prevents Statin-Dependent Myotoxicity in C2C12 Muscle Cells through RAP1 GTPase Prenylation and Cytoprotective Autophagy. Oxidative medicine and cellular longevity 2018; 2018:6463807. http://www.ncbi.nlm.nih.gov/pubmed/?term=29951166
  28. Rezazadeh M, Parandeh M, Akbari V et al. Incorporation of rosuvastatin-loaded chitosan/chondroitin sulfate nanoparticles into a thermosensitive hydrogel for bone tissue engineering: preparation, characterization, and cellular behavior. Pharmaceutical development and technology 2018:1-23. http://www.ncbi.nlm.nih.gov/pubmed/?term=29863957
  29. Wang X, Jia Z, Almoshari Y et al. Local Application of Pyrophosphorylated Simvastatin Prevents Experimental Periodontitis. Pharm Res 2018; 35:164. http://www.ncbi.nlm.nih.gov/pubmed/?term=29943090
  30. Kim MC, Yun SC, Lee SO et al. Statins increase the risk of herpes zoster: A propensity score-matched analysis. PLoS One 2018; 13:e0198263. http://www.ncbi.nlm.nih.gov/pubmed/?term=29902266
  31. Yamanaka JS, Ribeiro KEC, Yanagihara GR et al. Effects of simvastatin associated with exercise on the mechanical resistance of muscle and bone in rats. Revista brasileira de ortopedia 2018; 53:287-292. http://www.ncbi.nlm.nih.gov/pubmed/?term=29892578
  32. Lee JS, Roberts A, Juarez D et al. Statins enhance efficacy of venetoclax in blood cancers. Science translational medicine 2018; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29899021
  33. Huo Z, Kong Y, Meng M et al. Atorvastatin enhances endothelial adherens junctions through promoting VE-PTP gene transcription and reducing VE-cadherin-Y731 phosphorylation. Vascul Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29894844
  34. Du RX, Ye P, Yan GT et al. [The effect of rosuvastatin therapy on CCR2 expression in mononuclear cells and its upstream pathway]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 2016; 32:202-206. http://www.ncbi.nlm.nih.gov/pubmed/?term=29931877
  35. Hao WJ, Ke SZ, Liu L et al. [The experimental study of simvastatin on improving aspirin resistance in diabetic rats]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 2016; 32:395-400. http://www.ncbi.nlm.nih.gov/pubmed/?term=29931841
  36. Zhou CZ, Pan SL, Lin H et al. [Effects of rosuvastatin in homocysteine induced mouse vascular smooth muscle cell dedifferentiation and endoplasmic reticulum stress and its mechanisms]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 2018; 34:43-48. http://www.ncbi.nlm.nih.gov/pubmed/?term=29926658
  37. Ren H, Ding M, Ma H et al. [Protective effects of combined use of atorvastatin and low molecular weight heparin on the inflammatory reaction and pulmonary functions in rats with sepsis]. Zhonghua wei zhong bing ji jiu yi xue 2016; 28:427-432. http://www.ncbi.nlm.nih.gov/pubmed/?term=29920039

Cancer

  1. Jones HM, Fang Z, Sun W et al. Erratum: Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro. American journal of cancer research 2018; 8:915. http://www.ncbi.nlm.nih.gov/pubmed/?term=29888764
  2. Nguyen T, Khan A, Liu Y et al. The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. Am J Gastroenterol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29946180
  3. Chujan S, Suriyo T, Ungtrakul T et al. Potential candidate treatment agents for targeting of cholangiocarcinoma identified by gene expression profile analysis. Biomedical reports 2018; 9:42-52. http://www.ncbi.nlm.nih.gov/pubmed/?term=29930804
  4. Dong R, Ma G, Zhang S et al. Simvastatin reverses multiple myeloma serum-induced prothrombotic phenotype in endothelial cells via ERK 1/2 signalling pathway. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29916838
  5. Zhao J, Xu C, Yao J et al. Statins and Thyroid Carcinoma: a Meta-Analysis. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018; 47:1422-1431. http://www.ncbi.nlm.nih.gov/pubmed/?term=29929194
  6. Gambhire VM, Salunkhe SM, Gambhire MS. Atorvastatin loaded lipid nanoparticles: Antitumor activity studies on MCF-7 breast cancer cells. Drug development and industrial pharmacy 2018:1-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=29936872
  7. Chen YA, Shih HW, Lin YC et al. Simvastatin Sensitizes Radioresistant Prostate Cancer Cells by Compromising DNA Double-Strand Break Repair. Frontiers in pharmacology 2018; 9:600. http://www.ncbi.nlm.nih.gov/pubmed/?term=29950990
  8. Lebo NL, Griffiths R, Hall S et al. Effect of statin use on oncologic outcomes in head and neck squamous cell carcinoma. Head & neck 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29934959
  9. Dyg Sperling C, Verdoodt F, Kjaer Hansen M et al. Statin use and mortality among endometrial cancer patients: a Danish nationwide cohort study. International journal of cancer. Journal international du cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29923185
  10. Zhong WB, Tsai YC, Chin LH et al. A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model. Int J Mol Sci 2018; 19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29932104
  11. Borgquist S, Bjarnadottir O, Kimbung S, Ahern TP. Statins - a role in breast cancer therapy? Journal of internal medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29923256
  12. Tseng CH. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver international : official journal of the International Association for the Study of the Liver 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29956875
  13. Cai WY, Zhuang Y, Yan F et al. Effect of survivin downregulation by simvastatin on the growth and invasion of salivary adenoid cystic carcinoma. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29956779
  14. Jayalath VH, Nayan M, Finelli A et al. Statin use and time to progression in men on active surveillance for prostate cancer. Prostate Cancer Prostatic Dis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29875433
  15. Lee JS, Roberts A, Juarez D et al. Statins enhance efficacy of venetoclax in blood cancers. Science translational medicine 2018; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29899021
  16. Huo Z, Kong Y, Meng M et al. Atorvastatin enhances endothelial adherens junctions through promoting VE-PTP gene transcription and reducing VE-cadherin-Y731 phosphorylation. Vascul Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29894844

Children

  1. Epure AM, Leyvraz M, Mivelaz Y et al. Risk factors and determinants of carotid intima-media thickness in children: protocol for a systematic review and meta-analysis. BMJ Open 2018; 8:e019644. http://www.ncbi.nlm.nih.gov/pubmed/?term=29866720

Cost-effectiveness

  1. Soko ND, Masimirembwa C, Dandara C. A cost effective RFLP method to genotype Solute carrier organic anion 1B1 (SLCO1B1) c.1929A>C (p.Leu643Phe, rs34671512); a variant with potential effect on rosuvastatin pharmacokinetics. BMC research notes 2018; 11:384. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898760
  2. Chen S, Xiang Q, Zhao X et al. Impact of the 719Arg variant of KIF6 and major cardiovascular events on patients who received statins: a systematic review and meta-analysis. Current pharmaceutical design 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29938614
  3. Chen X, Barywani SB, Sigurjonsdottir R, Fu M. Improved short and long term survival associated with percutaneous coronary intervention in the elderly patients with acute coronary syndrome. BMC geriatrics 2018; 18:137. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898676
  4. Gitt AK, Lautsch D, Ferrieres J et al. Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world. Data in brief 2018; 18:1937-1940. http://www.ncbi.nlm.nih.gov/pubmed/?term=29904698
  5. Peng Y, Ou BQ, Li HH et al. Synergistic Effect of Atorvastatin and Folic Acid on Cardiac Function and Ventricular Remodeling in Chronic Heart Failure Patients with Hyperhomocysteinemia. Medical science monitor : international medical journal of experimental and clinical research 2018; 24:3744-3751. http://www.ncbi.nlm.nih.gov/pubmed/?term=29863106
  6. Tomilova DI, Karpov YA, Lopukhova VV. [Long-Term Statin Adherence in Patients with Stable Angina after Coronary Stenting]. Kardiologiia 2018:65-71. http://www.ncbi.nlm.nih.gov/pubmed/?term=29870326

Endothelium/inflammation

  1. Fuentes-Orozco C, Garcia-Salazar SJ, Gomez-Navarro B et al. Anti-Inflammatory Effect of Atorvastatin on the Kidney Graft of Living Donor Transplants. Annals of transplantation 2018; 23:442-449. http://www.ncbi.nlm.nih.gov/pubmed/?term=29955032
  2. Huo Z, Kong Y, Meng M et al. Atorvastatin enhances endothelial adherens junctions through promoting VE-PTP gene transcription and reducing VE-cadherin-Y731 phosphorylation. Vascul Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29894844
  3. Golab-Janowska M, Paczkowska E, Machalinski B et al. Statins therapy is associated with increased populations of early endothelial progenitor (CD133+/VEGFR2+) and endothelial (CD34-/CD133-/VEGFR2+) cells in patients with acute ischemic stroke. Current neurovascular research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29886830
  4. Mason RP, Dawoud H, Jacob RF et al. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 103:1231-1237. http://www.ncbi.nlm.nih.gov/pubmed/?term=29864903

Ethnicity

  1. Akouchekian S, Omranifard V, Moshfegh P et al. The Effect of Atorvastatin on Obsessive-compulsive Symptoms of Refractory Obsessive-compulsive Disorder (Add-on Therapy). Advanced biomedical research 2018; 7:90. http://www.ncbi.nlm.nih.gov/pubmed/?term=29930930
  2. Day J, Limaye V. Over-representation of statin-associated necrotising myopathy in patients of Aboriginal and Torres Strait Islander heritage. Internal medicine journal 2018; 48:749-751. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898279
  3. Choi J, Kim Y, Kim HS et al. Phenotyping of Korean patients with better-than-expected efficacy of moderate-intensity statins using tensor factorization. PLoS One 2018; 13:e0197518. http://www.ncbi.nlm.nih.gov/pubmed/?term=29897980
  4. Yan BP, Chiang FT, Ambegaonkar B et al. Low-density lipoprotein cholesterol target achievement in patients surviving an acute coronary syndrome in Hong Kong and Taiwan - findings from the Dyslipidemia International Study II. Int J Cardiol 2018; 265:1-5. http://www.ncbi.nlm.nih.gov/pubmed/?term=29885676

FH
  1. Hartgers ML, Besseling J, Stroes ES et al. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29934068
  2. Harada-Shiba M, Arai H, Ishigaki Y et al. Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29877295

Genetics

  1. Chen S, Xiang Q, Zhao X et al. Impact of the 719Arg variant of KIF6 and major cardiovascular events on patients who received statins: a systematic review and meta-analysis. Current pharmaceutical design 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29938614
  2. Abd Elgwad ER, Behiry EG, Swailem FM et al. Association between Q192R polymorphism in the PON1 gene and statin responses in cardiac patients. Annals of medicine and surgery (2012) 2018; 31:1-5. http://www.ncbi.nlm.nih.gov/pubmed/?term=29922459
  3. Soko ND, Masimirembwa C, Dandara C. A cost effective RFLP method to genotype Solute carrier organic anion 1B1 (SLCO1B1) c.1929A>C (p.Leu643Phe, rs34671512); a variant with potential effect on rosuvastatin pharmacokinetics. BMC research notes 2018; 11:384. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898760
  4. Brunham LR, Baker S, Mammen A et al. Role of Genetics in the Prediction of Statin-Associated Muscle Symptoms and Optimization of Statin Use and Adherence. Cardiovascular research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29878063

Guidelines

  1. Selak V, Webster R, Stepien S et al. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Heart 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29954855
  2. De Ferrari GM, Perna GP, Nicosia A et al. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy. Journal of cardiovascular medicine (Hagerstown, Md.) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29917002
  3. Goyal A, Cooper HA, Aronow WS et al. Use of Statins for Primary Prevention - Selection of Risk Threshold and Implications across Race and Gender. Am J Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29928863
  4. Lowenstern A, Li S, Navar AM et al. Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry. Am Heart J 2018; 200:118-124. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898839
  5. Miedema MD, Dardari ZA, Kianoush S et al. Statin Eligibility, Coronary Artery Calcium, and Subsequent Cardiovascular Events According to the 2016 United States Preventive Services Task Force (USPSTF) Statin Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29899017
  6. Harada-Shiba M, Arai H, Ishigaki Y et al. Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29877295/?term=29752030

LDL- related parameters

  1. Ho LT, Lin FJ, Tseng WK et al. On-treatment lipid profiles to predict the cardiovascular outcomes in ASCVD patients comorbid with chronic kidney disease - The multi-center T-SPARCLE registry study. Journal of the Formosan Medical Association = Taiwan yi zhi 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29945742
  2. Mazza A, Schiavon L, Rigatelli G et al. The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk. Food & function 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29951651
  3. Naidoo P, Mothilal R, Blom DJ. Therapeutic Management of Dyslipidemia Patients at Very High Cardiovascular Risk (CARDIO TRACK): Protocol for the Observational Registry Study. JMIR research protocols 2018; 7:e163. http://www.ncbi.nlm.nih.gov/pubmed/?term=29959115
  4. Wang WY, Zhang K, Zhao W et al. Free triiodothyronine level correlates with statin responsiveness in acute myocardial infarction. Journal of geriatric cardiology : JGC 2018; 15:290-297. http://www.ncbi.nlm.nih.gov/pubmed/?term=29915619
  5. De Ferrari GM, Perna GP, Nicosia A et al. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy. Journal of cardiovascular medicine (Hagerstown, Md.) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29917002
  6. Ballantyne CM, Banach M, Mancini GBJ et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29910030
  7. Ida J, Kotani K, Miyoshi T et al. High Baseline Lipoprotein(a) Level as a Risk Factor for Coronary Artery Calcification Progression: Sub-analysis of a Prospective Multicenter Trial. Acta medica Okayama 2018; 72:223-230. http://www.ncbi.nlm.nih.gov/pubmed/?term=29925999
  8. Choi J, Kim Y, Kim HS et al. Phenotyping of Korean patients with better-than-expected efficacy of moderate-intensity statins using tensor factorization. PLoS One 2018; 13:e0197518. http://www.ncbi.nlm.nih.gov/pubmed/?term=29897980
  9. Gitt AK, Lautsch D, Ferrieres J et al. Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world. Data in brief 2018; 18:1937-1940. http://www.ncbi.nlm.nih.gov/pubmed/?term=29904698
  10. Martin SS, Giugliano RP, Murphy SA et al. Comparison of Low-density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial. JAMA cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898218
  11. Packard CJ. Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias. Current cardiology reports 2018; 20:60. http://www.ncbi.nlm.nih.gov/pubmed/?term=29904807
  12. Yan BP, Chiang FT, Ambegaonkar B et al. Low-density lipoprotein cholesterol target achievement in patients surviving an acute coronary syndrome in Hong Kong and Taiwan - findings from the Dyslipidemia International Study II. Int J Cardiol 2018; 265:1-5. http://www.ncbi.nlm.nih.gov/pubmed/?term=29885676
  13. Chan DC, Watts GF, Somaratne R et al. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Arterioscler Thromb Vasc Biol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29880491

Lifestyle

  1. Ferrieres J, Lautsch D, Gitt AK et al. Body Mass Index impacts the choice of lipid lowering treatment with no correlation to blood cholesterol - findings from 52,916 patients in the Dyslipidemia International Study (DYSIS). Diabetes Obes Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29888459

Meta-analyses

  1. Chen S, Xiang Q, Zhao X et al. Impact of the 719Arg variant of KIF6 and major cardiovascular events on patients who received statins: a systematic review and meta-analysis. Current pharmaceutical design 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29938614
  2. Meza-Mauricio J, Soto-Penaloza D, Penarrocha-Oltra D et al. Locally applied statins as adjuvants to non-surgical periodontal treatment for chronic periodontitis: a systematic review and meta-analysis. Clinical oral investigations 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29948277
  3. Selak V, Webster R, Stepien S et al. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Heart 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29954855
  4. Yu W, Wang B, Zhan B et al. Statin therapy improved long-term prognosis in patients with major non-cardiac vascular surgeries: a systematic review and meta-analysis. Vascul Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29953967
  5. Zhao J, Xu C, Yao J et al. Statins and Thyroid Carcinoma: a Meta-Analysis. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018; 47:1422-1431. http://www.ncbi.nlm.nih.gov/pubmed/?term=29929194
  6. Feng Y. Efficacy of statin therapy in patients with acute respiratory distress syndrome/acute lung injury: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2018; 22:3190-3198. http://www.ncbi.nlm.nih.gov/pubmed/?term=29863265
  7. Epure AM, Leyvraz M, Mivelaz Y et al. Risk factors and determinants of carotid intima-media thickness in children: protocol for a systematic review and meta-analysis. BMJ Open 2018; 8:e019644. http://www.ncbi.nlm.nih.gov/pubmed/?term=29866720
  8. Uthman OA, Nduka C, Watson SI et al. Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis. BMC infectious diseases 2018; 18:258. http://www.ncbi.nlm.nih.gov/pubmed/?term=29866059
Metabolic syndrome - Diabetes
  1. Tseng CH. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver international : official journal of the International Association for the Study of the Liver 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29956875
  2. Rodriguez V, Newman JD, Schwartzbard AZ. Towards more specific treatment for diabetic dyslipidemia. Curr Opin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29878904

New Treatments

  1. Brandt EJ, Benes LB, Lee L et al. The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. Journal of cardiovascular pharmacology and therapeutics 2018:1074248418780733. http://www.ncbi.nlm.nih.gov/pubmed/?term=29940784
  2. Ikegami Y, Inoue I, Inoue K et al. The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. NPJ aging and mechanisms of disease 2018; 4:7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29951223
  3. Zagelbaum NK, Yandrapalli S, Nabors C, Frishman WH. Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review Of A First In Class Medication With Potential Benefit In Statin-Refractory Cases. Cardiology in review 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29939848
  4. Ballantyne CM, Banach M, Mancini GBJ et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29910030
  5. Reiss AB, Shah N, Muhieddine D et al. PCSK9 in cholesterol metabolism: from bench to bedside. Clinical science (London, England : 1979) 2018; 132:1135-1153. http://www.ncbi.nlm.nih.gov/pubmed/?term=29895529
  6. Firnhaber JM. Newer cholesterol-lowering agents: What you must know. The Journal of family practice 2018; 67:339;341;344;345. http://www.ncbi.nlm.nih.gov/pubmed/?term=29879234
  7. Gao WY, Chen PY, Chen SF et al. Pinostrobin inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression through the modulation of FoxO3a protein in HepG2 cells. Journal of agricultural and food chemistry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29862818
  8. Rodriguez V, Newman JD, Schwartzbard AZ. Towards more specific treatment for diabetic dyslipidemia. Curr Opin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29878904
  9. Zafrir B, Jubran A. Lipid-lowering Therapy with PCSK9-inhibitors in the Real World Setting: Two-year Experience of a Regional Lipid clinic. Cardiovasc Ther 2018:e12439. http://www.ncbi.nlm.nih.gov/pubmed/?term=29863817
  10. Chan DC, Watts GF, Somaratne R et al. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Arterioscler Thromb Vasc Biol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29880491

Other

  1. Litke J, Spoutz L, Ahlstrom D et al. Impact of the clinical pharmacy specialist in telehealth primary care. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2018; 75:982-986. http://www.ncbi.nlm.nih.gov/pubmed/?term=29941537
  2. Rezende LFM, Rey-Lopez JP, Sa TH et al. Reporting bias in the literature on the associations of health-related behaviors and statins with cardiovascular disease and all-cause mortality. PLoS biology 2018; 16:e2005761. http://www.ncbi.nlm.nih.gov/pubmed/?term=29912869
  3. Wang WY, Zhang K, Zhao W et al. Free triiodothyronine level correlates with statin responsiveness in acute myocardial infarction. Journal of geriatric cardiology : JGC 2018; 15:290-297. http://www.ncbi.nlm.nih.gov/pubmed/?term=29915619
  4. Ananwattanasuk T, Chiewchalermsri C, Tongdee P, Nimkuntod P. Venipuncture Rate of Liver Function Tests for Patients being Treatment with Statin in Clinical Practice: A Therapeutic Dilemma. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2016; 99 Suppl 7:S69-75. http://www.ncbi.nlm.nih.gov/pubmed/?term=29901925
  5. Verbree-Willemsen L, Zhang YN, Gijsberts CM et al. LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trial. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898827
  6. Cholan RA, Weiskopf NG, Rhoton D et al. From Concepts and Codes to Healthcare Quality Measurement: Understanding Variations in Value Set Vocabularies for a Statin Therapy Clinical Quality Measure. EGEMS (Washington, DC) 2017; 5:19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29881739
  7. Lin CY. Immortal Time Bias Can Occur in the Analysis of Dose-Dependent Effect of Statin. Chest 2018; 153:1508-1509. http://www.ncbi.nlm.nih.gov/pubmed/?term=29884263

PAD and statins

  1. Thiney M, Della Schiava N, Ecochard R et al. Effects on mortality and cardiovascular events of adherence to guideline-recommended therapy 4 years after lower extremity arterial revascularization. Annals of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29777848

Pleiotropic effects of statins

  1. Kang JH, Kao LT, Lin HC et al. Do outpatient statins and ACEIs/ARBs have synergistic effects in reducing the risk of pneumonia? A population-based case-control study. PLoS One 2018; 13:e0199981. http://www.ncbi.nlm.nih.gov/pubmed/?term=29953536
  2. Meza-Mauricio J, Soto-Penaloza D, Penarrocha-Oltra D et al. Locally applied statins as adjuvants to non-surgical periodontal treatment for chronic periodontitis: a systematic review and meta-analysis. Clinical oral investigations 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29948277
  3. Tseng CH. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver international : official journal of the International Association for the Study of the Liver 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29956875
  4. Usategui-Martin R, Vega G, Abad-Manteca L et al. Role of Bone Morphogenetic Protein 2 (BMP-2) Polymorphisms in Bone Mineral Density after the Start of Treatment with Atorvastatin. Basic & clinical pharmacology & toxicology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29956474
  5. Villani C, Sacchetti G, Bagnati R et al. Correction: Lovastatin fails to improve motor performance and survival in methyl-CpG-binding protein2-null mice. eLife 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29957179
  6. Wang X, Jia Z, Almoshari Y et al. Local Application of Pyrophosphorylated Simvastatin Prevents Experimental Periodontitis. Pharm Res 2018; 35:164. http://www.ncbi.nlm.nih.gov/pubmed/?term=29943090
  7. Yu W, Wang B, Zhan B et al. Statin therapy improved long-term prognosis in patients with major non-cardiac vascular surgeries: a systematic review and meta-analysis. Vascul Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29953967
  8. Hao WJ, Ke SZ, Liu L et al. [The experimental study of simvastatin on improving aspirin resistance in diabetic rats]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 2016; 32:395-400. http://www.ncbi.nlm.nih.gov/pubmed/?term=29931841
  9. Forouzanfar F, Butler AE, Banach M et al. Modulation of heat shock proteins by statins. Pharmacol Res 2018; 134:134-144. http://www.ncbi.nlm.nih.gov/pubmed/?term=29935271
  10. Nakashima Y, Miyagi-Shiohira C, Noguchi H, Omasa T. Atorvastatin Inhibits the HIF1alpha-PPAR Axis, Which Is Essential for Maintaining the Function of Human Induced Pluripotent Stem Cells. Molecular therapy : the journal of the American Society of Gene Therapy 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29929789
  11. Mohammadian M, Sadeghipour HR, Jahromi GP et al. Simvastatin and bone marrow-derived mesenchymal stem cells (BMSCs) affects serum IgE and lung cytokines levels in sensitized mice. Cytokine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29914792
  12. Dong R, Ma G, Zhang S et al. Simvastatin reverses multiple myeloma serum-induced prothrombotic phenotype in endothelial cells via ERK 1/2 signalling pathway. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29916838
  13. Akouchekian S, Omranifard V, Moshfegh P et al. The Effect of Atorvastatin on Obsessive-compulsive Symptoms of Refractory Obsessive-compulsive Disorder (Add-on Therapy). Advanced biomedical research 2018; 7:90. http://www.ncbi.nlm.nih.gov/pubmed/?term=29930930
  14. Santos C, Dourado DM, Silva B et al. Effect of Ischemic Postconditioning and Atorvastatin in the Prevention of Remote Lung Reperfusion Injury. Brazilian journal of cardiovascular surgery 2018; 33:115-121. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898139
  15. Hadzi-Petrushev N, Dimovska K, Jankulovski N et al. Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease's Statin Therapy in Men. Advances in pharmacological sciences 2018; 2018:4673061. http://www.ncbi.nlm.nih.gov/pubmed/?term=29887885
  16. Kamari VE, Hileman CO, Gholam PM et al. Statin Therapy Does Not Reduce Liver Fat Scores in Patients Receiving Antiretroviral Therapy for HIV Infection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29908359
  17. Simon TG, Corey KE, Cannon CP et al. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29903515
  18. Jurisic A, Jurisic Z, Lefkou E et al. Pravastatin and-L-arginine combination improves umbilical artery blood flow and neonatal outcomes in dichorionic twin pregnancies through an nitric oxide-dependent vasorelaxant effect. Vascul Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29879462
  19. Wegner A, Pavlovic D, Haussmann-Vopel S, Lehmann C. Impact of lipid modulation on the intestinal microcirculation in experimental sepsis. Microvascular research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29859746
  20. Tong H, Zhang X, Meng X et al. Simvastatin Inhibits Activation of NADPH Oxidase/p38 MAPK Pathway and Enhances Expression of Antioxidant Protein in Parkinson Disease Models. Frontiers in molecular neuroscience 2018; 11:165. http://www.ncbi.nlm.nih.gov/pubmed/?term=29872377
  21. Feng Y. Efficacy of statin therapy in patients with acute respiratory distress syndrome/acute lung injury: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2018; 22:3190-3198. http://www.ncbi.nlm.nih.gov/pubmed/?term=29863265
  22. Burkard T, Huegle T, Layton JB et al. The risk of incident osteoarthritis of the hand in statin initiators:A sequential cohort study. Arthritis care & research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29885074

Primary Prevention

  1. Goyal A, Cooper HA, Aronow WS et al. Use of Statins for Primary Prevention - Selection of Risk Threshold and Implications across Race and Gender. Am J Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29928863

Registry data

  1. Dave CV, Winterstein AG, Park H et al. Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study. Journal of affective disorders 2018; 238:542-546. http://www.ncbi.nlm.nih.gov/pubmed/?term=29936394
  2. Ho LT, Lin FJ, Tseng WK et al. On-treatment lipid profiles to predict the cardiovascular outcomes in ASCVD patients comorbid with chronic kidney disease - The multi-center T-SPARCLE registry study. Journal of the Formosan Medical Association = Taiwan yi zhi 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29945742
  3. Naidoo P, Mothilal R, Blom DJ. Therapeutic Management of Dyslipidemia Patients at Very High Cardiovascular Risk (CARDIO TRACK): Protocol for the Observational Registry Study. JMIR research protocols 2018; 7:e163. http://www.ncbi.nlm.nih.gov/pubmed/?term=29959115
  4. Nguyen T, Khan A, Liu Y et al. The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. Am J Gastroenterol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29946180
  5. Whyte J, Ketchum J, Bogner JA et al. The Effects of Statin Treatment on Outcomes following Traumatic Brain Injury. Journal of neurotrauma 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29954258
  6. Lee SE, Chang HJ, Sung JM et al. Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM (Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging) Study. JACC. Cardiovascular imaging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29909109
  7. Rizwan M, Faateh M, Aridi HD et al. Statins reduce mortality and failure to rescue after carotid artery stenting. Journal of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29914834
  8. Borgquist S, Bjarnadottir O, Kimbung S, Ahern TP. Statins - a role in breast cancer therapy? Journal of internal medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29923256
  9. Wang WY, Zhang K, Zhao W et al. Free triiodothyronine level correlates with statin responsiveness in acute myocardial infarction. Journal of geriatric cardiology : JGC 2018; 15:290-297. http://www.ncbi.nlm.nih.gov/pubmed/?term=29915619
  10. Hartgers ML, Besseling J, Stroes ES et al. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29934068
  11. De Ferrari GM, Perna GP, Nicosia A et al. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy. Journal of cardiovascular medicine (Hagerstown, Md.) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29917002
  12. Dyg Sperling C, Verdoodt F, Kjaer Hansen M et al. Statin use and mortality among endometrial cancer patients: a Danish nationwide cohort study. International journal of cancer. Journal international du cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29923185
  13. Lebo NL, Griffiths R, Hall S et al. Effect of statin use on oncologic outcomes in head and neck squamous cell carcinoma. Head & neck 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29934959
  14. Skeldon SC, Carleton B, Brophy J et al. Statin Medications and the Risk of Gynecomastia. Clinical endocrinology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29923212
  15. Abd Elgwad ER, Behiry EG, Swailem FM et al. Association between Q192R polymorphism in the PON1 gene and statin responses in cardiac patients. Annals of medicine and surgery (2012) 2018; 31:1-5. http://www.ncbi.nlm.nih.gov/pubmed/?term=29922459
  16. Kim MC, Yun SC, Lee SO et al. Statins increase the risk of herpes zoster: A propensity score-matched analysis. PLoS One 2018; 13:e0198263. http://www.ncbi.nlm.nih.gov/pubmed/?term=29902266
  17. Lowenstern A, Li S, Navar AM et al. Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry. Am Heart J 2018; 200:118-124. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898839
  18. Musich S, Wang SS, Schwebke K et al. Underutilization of Statin Therapy for Secondary Prevention of Cardiovascular Disease Among Older Adults. Population health management 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29893617
  19. Nanna MG, Navar AM, Zakroysky P et al. Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry. JAMA cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898219
  20. Chee WJ, Abdullahi H, Chan Y et al. Retrospective Evaluation of Statin Prescription in the Elderly. Internal medicine journal 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29869449
  21. Burkard T, Huegle T, Layton JB et al. The risk of incident osteoarthritis of the hand in statin initiators:A sequential cohort study. Arthritis care & research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29885074

Renal Disease

  1. Fuentes-Orozco C, Garcia-Salazar SJ, Gomez-Navarro B et al. Anti-Inflammatory Effect of Atorvastatin on the Kidney Graft of Living Donor Transplants. Annals of transplantation 2018; 23:442-449. http://www.ncbi.nlm.nih.gov/pubmed/?term=29955032
  2. Ho LT, Lin FJ, Tseng WK et al. On-treatment lipid profiles to predict the cardiovascular outcomes in ASCVD patients comorbid with chronic kidney disease - The multi-center T-SPARCLE registry study. Journal of the Formosan Medical Association = Taiwan yi zhi 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29945742
  3. Vershinina EO, Repin AN, Timofeev MS, Udut VV. [Prevention of periprocedural kidney ingury by loading doses of statins in elective percutaneous small es, Cyrillicoronary interventions]. Kardiologiia 2018:20-29. http://www.ncbi.nlm.nih.gov/pubmed/?term=29894673

Reviews

  1. Banach M, Patti AM, Giglio RV et al. The Role of Nutraceuticals in Statin Intolerant Patients. J Am Coll Cardiol 2018; 72:96-118. http://www.ncbi.nlm.nih.gov/pubmed/?term=29957236
  2. Verdoia M, Galasso G, Filardi PP, De Luca G. Statins and elderly: from clinical trials to daily practice. Current vascular pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29956633
  3. Zagelbaum NK, Yandrapalli S, Nabors C, Frishman WH. Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review Of A First In Class Medication With Potential Benefit In Statin-Refractory Cases. Cardiology in review 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29939848
  4. Rezende LFM, Rey-Lopez JP, Sa TH et al. Reporting bias in the literature on the associations of health-related behaviors and statins with cardiovascular disease and all-cause mortality. PLoS biology 2018; 16:e2005761. http://www.ncbi.nlm.nih.gov/pubmed/?term=29912869
  5. Bird JK, Calder PC, Eggersdorfer M. The Role of n-3 Long Chain Polyunsaturated Fatty Acids in Cardiovascular Disease Prevention, and Interactions with Statins. Nutrients 2018; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29914111
  6. Pitavastatin magnesium (Zypitamag) for hyperlipidemia. The Medical letter on drugs and therapeutics 2018; 60:106. http://www.ncbi.nlm.nih.gov/pubmed/?term=29913475
  7. Martin SS, Giugliano RP, Murphy SA et al. Comparison of Low-density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial. JAMA cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898218
  8. Packard CJ. Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias. Current cardiology reports 2018; 20:60. http://www.ncbi.nlm.nih.gov/pubmed/?term=29904807
  9. Reiss AB, Shah N, Muhieddine D et al. PCSK9 in cholesterol metabolism: from bench to bedside. Clinical science (London, England : 1979) 2018; 132:1135-1153. http://www.ncbi.nlm.nih.gov/pubmed/?term=29895529
  10. Tsivgoulis G, Safouris A, Kim DE, Alexandrov AV. Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke. J Stroke 2018; 20:145-166. http://www.ncbi.nlm.nih.gov/pubmed/?term=29886715
  11. Lansberg P, Lee A, Lee ZV et al. Nonadherence to statins: individualized intervention strategies outside the pill box. Vasc Health Risk Manag 2018; 14:91-102. http://www.ncbi.nlm.nih.gov/pubmed/?term=29872306
  12. Jayalath VH, Nayan M, Finelli A et al. Statin use and time to progression in men on active surveillance for prostate cancer. Prostate Cancer Prostatic Dis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29875433
  13. Firnhaber JM. Newer cholesterol-lowering agents: What you must know. The Journal of family practice 2018; 67:339;341;344;345. http://www.ncbi.nlm.nih.gov/pubmed/?term=29879234
  14. Shekar C, Budoff M. Calcification of the heart: mechanisms and therapeutic avenues. Expert Rev Cardiovasc Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29860888
  15. Cholan RA, Weiskopf NG, Rhoton D et al. From Concepts and Codes to Healthcare Quality Measurement: Understanding Variations in Value Set Vocabularies for a Statin Therapy Clinical Quality Measure. EGEMS (Washington, DC) 2017; 5:19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29881739
  16. Rodriguez V, Newman JD, Schwartzbard AZ. Towards more specific treatment for diabetic dyslipidemia. Curr Opin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29878904
  17. Zafrir B, Jubran A. Lipid-lowering Therapy with PCSK9-inhibitors in the Real World Setting: Two-year Experience of a Regional Lipid clinic. Cardiovasc Ther 2018:e12439. http://www.ncbi.nlm.nih.gov/pubmed/?term=29863817
  18. Brunham LR, Baker S, Mammen A et al. Role of Genetics in the Prediction of Statin-Associated Muscle Symptoms and Optimization of Statin Use and Adherence. Cardiovascular research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29878063

Safety and side effects

  1. Bai X, Zhang B, Wang P et al. Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. Acta pharmacologica Sinica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29950617
  2. Banach M, Patti AM, Giglio RV et al. The Role of Nutraceuticals in Statin Intolerant Patients. J Am Coll Cardiol 2018; 72:96-118. http://www.ncbi.nlm.nih.gov/pubmed/?term=29957236
  3. Chen L, Liu L, Chen Y et al. Modulation of transporter activity of OATP1B1 and OATP1B3 by the major active components of Radix Ophiopogonis. Xenobiotica 2018:1-22. http://www.ncbi.nlm.nih.gov/pubmed/?term=29944058
  4. Dave CV, Winterstein AG, Park H et al. Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study. Journal of affective disorders 2018; 238:542-546. http://www.ncbi.nlm.nih.gov/pubmed/?term=29936394
  5. Hamdan AL, Mourad M, Fakhri G et al. Vocal tract symptoms: Severity and frequency in patients on statins. Ear, nose, & throat journal 2018; 97:128-136. http://www.ncbi.nlm.nih.gov/pubmed/?term=29940682
  6. Jaskiewicz A, Pajak B, Litwiniuk A et al. Geranylgeraniol Prevents Statin-Dependent Myotoxicity in C2C12 Muscle Cells through RAP1 GTPase Prenylation and Cytoprotective Autophagy. Oxidative medicine and cellular longevity 2018; 2018:6463807. http://www.ncbi.nlm.nih.gov/pubmed/?term=29951166
  7. Mizrahi M, Adar T, Lalazar G et al. Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for "Safer Drug" Formulation that Prevents Drug-induced Liver Injury. Journal of clinical and translational hepatology 2018; 6:127-134. http://www.ncbi.nlm.nih.gov/pubmed/?term=29951356
  8. Taylor BA, Panza G, Ballard KD et al. Creatine supplementation does not alter the creatine kinase response to eccentric exercise in healthy adults on atorvastatin. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29945780
  9. de Sa A, Hart DA, Khan K, Scott A. Achilles tendon structure is negatively correlated with body mass index, but not influenced by statin use: A cross-sectional study using ultrasound tissue characterization. PLoS One 2018; 13:e0199645. http://www.ncbi.nlm.nih.gov/pubmed/?term=29928054
  10. Toure PS, Leye YM, Diop MM et al. [Thrombocytopenia purpura, myositis and cytolitic hepatitis: a rare association linked with atorvastatin]. Le Mali medical 2013; 28:49-51. http://www.ncbi.nlm.nih.gov/pubmed/?term=29925222
  11. Nunez-Manchon J, Ballester-Lopez A, Koehorst E et al. Manifesting heterozygotes in McArdle disease: a myth or a reality-role of statins. Journal of inherited metabolic disease 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29926259
  12. Vilahur G, Ben-Aicha S, Diaz E et al. Phytosterols and inflammation. Curr Med Chem 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29932029
  13. Yoshida K, Guo C, Sane R. Quantitative prediction of OATP-mediated drug-drug interactions with model-based analysis of endogenous biomarker kinetics. CPT Pharmacometrics Syst Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29924471
  14. Skeldon SC, Carleton B, Brophy J et al. Statin Medications and the Risk of Gynecomastia. Clinical endocrinology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29923212
  15. Ballantyne CM, Banach M, Mancini GBJ et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29910030
  16. Lemaster KA, Frisbee SJ, DuBois L et al. CHRONIC ATORVASTATIN AND EXERCISE CAN PARTIALLY REVERSE ESTABLISHED SKELETAL MUSCLE MICROVASCULOPATHY IN METABOLIC SYNDROME. American journal of physiology. Heart and circulatory physiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29932769
  17. Ananwattanasuk T, Chiewchalermsri C, Tongdee P, Nimkuntod P. Venipuncture Rate of Liver Function Tests for Patients being Treatment with Statin in Clinical Practice: A Therapeutic Dilemma. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2016; 99 Suppl 7:S69-75. http://www.ncbi.nlm.nih.gov/pubmed/?term=29901925
  18. Day J, Limaye V. Over-representation of statin-associated necrotising myopathy in patients of Aboriginal and Torres Strait Islander heritage. Internal medicine journal 2018; 48:749-751. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898279
  19. Yamanaka JS, Ribeiro KEC, Yanagihara GR et al. Effects of simvastatin associated with exercise on the mechanical resistance of muscle and bone in rats. Revista brasileira de ortopedia 2018; 53:287-292. http://www.ncbi.nlm.nih.gov/pubmed/?term=29892578
  20. Kim MC, Yun SC, Lee SO et al. Statins increase the risk of herpes zoster: A propensity score-matched analysis. PLoS One 2018; 13:e0198263. http://www.ncbi.nlm.nih.gov/pubmed/?term=29902266
  21. Soko ND, Masimirembwa C, Dandara C. A cost effective RFLP method to genotype Solute carrier organic anion 1B1 (SLCO1B1) c.1929A>C (p.Leu643Phe, rs34671512); a variant with potential effect on rosuvastatin pharmacokinetics. BMC research notes 2018; 11:384. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898760
  22. Chee WJ, Abdullahi H, Chan Y et al. Retrospective Evaluation of Statin Prescription in the Elderly. Internal medicine journal 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29869449
  23. Athyros VG, Katsiki N, Mikhailidis DP. Statins and substantially increased ALT values at baseline. Cardiovasc Ther 2018:e12444. http://www.ncbi.nlm.nih.gov/pubmed/?term=29883041
  24. Brunham LR, Baker S, Mammen A et al. Role of Genetics in the Prediction of Statin-Associated Muscle Symptoms and Optimization of Statin Use and Adherence. Cardiovascular research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29878063
  25. Barros S, Montes R, Quintana JB et al. Chronic environmentally relevant levels of simvastatin disrupt embryonic development, biochemical and molecular responses in zebrafish (Danio rerio). Aquatic toxicology (Amsterdam, Netherlands) 2018; 201:47-57. http://www.ncbi.nlm.nih.gov/pubmed/?term=29879595

Stroke and CNS

  1. Whyte J, Ketchum J, Bogner JA et al. The Effects of Statin Treatment on Outcomes following Traumatic Brain Injury. Journal of neurotrauma 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29954258
  2. Tang R, Shi J, Li X et al. Effects of Atorvastatin on Surgical Treatments of Chronic Subdural Hematoma. World neurosurgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29920396
  3. Rizwan M, Faateh M, Aridi HD et al. Statins reduce mortality and failure to rescue after carotid artery stenting. Journal of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29914834
  4. Kozlov SG, Khamchieva LS, Pogorelova OA et al. [Dynamics of asymptomatic atherosclerosis of carotid arteries depending on the achieved level of cholesterol in moderate-risk patients]. Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery 2018; 24:11-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=29924771
  5. Akouchekian S, Omranifard V, Moshfegh P et al. The Effect of Atorvastatin on Obsessive-compulsive Symptoms of Refractory Obsessive-compulsive Disorder (Add-on Therapy). Advanced biomedical research 2018; 7:90. http://www.ncbi.nlm.nih.gov/pubmed/?term=29930930
  6. Golab-Janowska M, Paczkowska E, Machalinski B et al. Statins therapy is associated with increased populations of early endothelial progenitor (CD133+/VEGFR2+) and endothelial (CD34-/CD133-/VEGFR2+) cells in patients with acute ischemic stroke. Current neurovascular research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29886830
  7. Bohula EA, Wiviott SD, Giugliano RP et al. Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 137:2662-2663. http://www.ncbi.nlm.nih.gov/pubmed/?term=29891625
  8. Cordero A, Bertomeu-Gonzalez V, Rodriguez-Manero M. Letter by Cordero et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 137:2658-2659. http://www.ncbi.nlm.nih.gov/pubmed/?term=29891623
  9. Thomopoulos C, Michalopoulou H. Letter by Thomopoulos and Michalopoulou Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 137:2656-2657. http://www.ncbi.nlm.nih.gov/pubmed/?term=29891622
  10. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. N Engl J Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898369
  11. Tsivgoulis G, Safouris A, Kim DE, Alexandrov AV. Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke. J Stroke 2018; 20:145-166. http://www.ncbi.nlm.nih.gov/pubmed/?term=29886715
  12. Tong H, Zhang X, Meng X et al. Simvastatin Inhibits Activation of NADPH Oxidase/p38 MAPK Pathway and Enhances Expression of Antioxidant Protein in Parkinson Disease Models. Frontiers in molecular neuroscience 2018; 11:165. http://www.ncbi.nlm.nih.gov/pubmed/?term=29872377  

Triglycerides/HDL

  1. Chan DC, Watts GF, Somaratne R et al. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Arterioscler Thromb Vasc Biol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29880491

Trials

  1. Brandt EJ, Benes LB, Lee L et al. The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. Journal of cardiovascular pharmacology and therapeutics 2018:1074248418780733. http://www.ncbi.nlm.nih.gov/pubmed/?term=29940784
  2. Fuentes-Orozco C, Garcia-Salazar SJ, Gomez-Navarro B et al. Anti-Inflammatory Effect of Atorvastatin on the Kidney Graft of Living Donor Transplants. Annals of transplantation 2018; 23:442-449. http://www.ncbi.nlm.nih.gov/pubmed/?term=29955032
  3. Hamdan AL, Mourad M, Fakhri G et al. Vocal tract symptoms: Severity and frequency in patients on statins. Ear, nose, & throat journal 2018; 97:128-136. http://www.ncbi.nlm.nih.gov/pubmed/?term=29940682
  4. Ikegami Y, Inoue I, Inoue K et al. The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. NPJ aging and mechanisms of disease 2018; 4:7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29951223
  5. Litke J, Spoutz L, Ahlstrom D et al. Impact of the clinical pharmacy specialist in telehealth primary care. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2018; 75:982-986. http://www.ncbi.nlm.nih.gov/pubmed/?term=29941537
  6. Mazza A, Schiavon L, Rigatelli G et al. The short-term supplementation of monacolin K improves the lipid and metabolic patterns of hypertensive and hypercholesterolemic subjects at low cardiovascular risk. Food & function 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29951651
  7. Turk Veselic M, Zorz N, Erzen B et al. Improvement of arterial wall phenotype in subjects at moderate cardiovascular risk induced by very low-dose fluvastatin/valsartan combination: a pilot study. International angiology : a journal of the International Union of Angiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29952159
  8. Nunez-Manchon J, Ballester-Lopez A, Koehorst E et al. Manifesting heterozygotes in McArdle disease: a myth or a reality-role of statins. Journal of inherited metabolic disease 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29926259
  9. Fujisue K, Nagamatsu S, Shimomura H et al. Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29925472
  10. Burton JK, Papworth R, Haig C et al. Statin Use is Not Associated with Future Long-Term Care Admission: Extended Follow-Up of Two Randomised Controlled Trials. Drugs Aging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29916140
  11. Ballantyne CM, Banach M, Mancini GBJ et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29910030
  12. Kozlov SG, Khamchieva LS, Pogorelova OA et al. [Dynamics of asymptomatic atherosclerosis of carotid arteries depending on the achieved level of cholesterol in moderate-risk patients]. Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery 2018; 24:11-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=29924771
  13. Lemaster KA, Frisbee SJ, DuBois L et al. Chronic Atorvastatin and Exercise Can Partially Reverse Established Skeletal Muscle Microvasculopathy in Metabolic Syndrome. American journal of physiology. Heart and circulatory physiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29932769
  14. Golab-Janowska M, Paczkowska E, Machalinski B et al. Statins therapy is associated with increased populations of early endothelial progenitor (CD133+/VEGFR2+) and endothelial (CD34-/CD133-/VEGFR2+) cells in patients with acute ischemic stroke. Current neurovascular research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29886830
  15. Bohula EA, Wiviott SD, Giugliano RP et al. Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 137:2662-2663. http://www.ncbi.nlm.nih.gov/pubmed/?term=29891625
  16. Chen X, Barywani SB, Sigurjonsdottir R, Fu M. Improved short and long term survival associated with percutaneous coronary intervention in the elderly patients with acute coronary syndrome. BMC geriatrics 2018; 18:137. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898676
  17. Cordero A, Bertomeu-Gonzalez V, Rodriguez-Manero M. Letter by Cordero et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 137:2658-2659. http://www.ncbi.nlm.nih.gov/pubmed/?term=29891623
  18. Del Pinto R, Ferri C, Borghi C. Letter by Del Pinto et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 137:2654-2655. http://www.ncbi.nlm.nih.gov/pubmed/?term=29891621
  19. Koh KK. Letter by Koh Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 137:2660-2661. http://www.ncbi.nlm.nih.gov/pubmed/?term=29891624
  20. Thomopoulos C, Michalopoulou H. Letter by Thomopoulos and Michalopoulou Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation 2018; 137:2656-2657. http://www.ncbi.nlm.nih.gov/pubmed/?term=29891622
  21. Verbree-Willemsen L, Zhang YN, Gijsberts CM et al. LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trial. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898827
  22. Vershinina EO, Repin AN, Timofeev MS, Udut VV. [Prevention of periprocedural kidney ingury by loading doses of statins in elective percutaneous small es, Cyrillicoronary interventions]. Kardiologiia 2018:20-29. http://www.ncbi.nlm.nih.gov/pubmed/?term=29894673
  23. Ferrieres J, Lautsch D, Gitt AK et al. Body Mass Index impacts the choice of lipid lowering treatment with no correlation to blood cholesterol - findings from 52,916 patients in the Dyslipidemia International Study (DYSIS). Diabetes Obes Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29888459
  24. Gitt AK, Lautsch D, Ferrieres J et al. Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world. Data in brief 2018; 18:1937-1940. http://www.ncbi.nlm.nih.gov/pubmed/?term=29904698
  25. Kamari VE, Hileman CO, Gholam PM et al. Statin Therapy Does Not Reduce Liver Fat Scores in Patients Receiving Antiretroviral Therapy for HIV Infection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29908359
  26. Simon TG, Corey KE, Cannon CP et al. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29903515
  27. Yan BP, Chiang FT, Ambegaonkar B et al. Low-density lipoprotein cholesterol target achievement in patients surviving an acute coronary syndrome in Hong Kong and Taiwan - findings from the Dyslipidemia International Study II. Int J Cardiol 2018; 265:1-5. http://www.ncbi.nlm.nih.gov/pubmed/?term=29885676
  28. Peng Y, Ou BQ, Li HH et al. Synergistic Effect of Atorvastatin and Folic Acid on Cardiac Function and Ventricular Remodeling in Chronic Heart Failure Patients with Hyperhomocysteinemia. Medical science monitor : international medical journal of experimental and clinical research 2018; 24:3744-3751. http://www.ncbi.nlm.nih.gov/pubmed/?term=29863106
  29. Deloughery EP, Prasad V. If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis. Journal of general internal medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29869138
  30. Athyros VG, Katsiki N, Mikhailidis DP. Statins and substantially increased ALT values at baseline. Cardiovasc Ther 2018:e12444. http://www.ncbi.nlm.nih.gov/pubmed/?term=29883041
  31. Mason RP, Dawoud H, Jacob RF et al. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 103:1231-1237. http://www.ncbi.nlm.nih.gov/pubmed/?term=29864903
  32. Chan DC, Watts GF, Somaratne R et al. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Arterioscler Thromb Vasc Biol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29880491

Women and elderly

  1. Verdoia M, Galasso G, Filardi PP, De Luca G. Statins and elderly: from clinical trials to daily practice. Current vascular pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29956633
  2. Dyg Sperling C, Verdoodt F, Kjaer Hansen M et al. Statin use and mortality among endometrial cancer patients: a Danish nationwide cohort study. International journal of cancer. Journal international du cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29923185
  3. Chen X, Barywani SB, Sigurjonsdottir R, Fu M. Improved short and long term survival associated with percutaneous coronary intervention in the elderly patients with acute coronary syndrome. BMC geriatrics 2018; 18:137. http://www.ncbi.nlm.nih.gov/pubmed/?term=29898676
  4. Musich S, Wang SS, Schwebke K et al. Underutilization of Statin Therapy for Secondary Prevention of Cardiovascular Disease Among Older Adults. Population health management 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29893617
  5. Jurisic A, Jurisic Z, Lefkou E et al. Pravastatin and-L-arginine combination improves umbilical artery blood flow and neonatal outcomes in dichorionic twin pregnancies through an nitric oxide-dependent vasorelaxant effect. Vascul Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29879462
  6. Chee WJ, Abdullahi H, Chan Y et al. Retrospective Evaluation of Statin Prescription in the Elderly. Internal medicine journal 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29869449

Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.